Covid-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: The patients will take resveratrol capsules(99% pure, Biotivia, Bioceuticals International SrI, and Italy? 250 mg, 3 times /day, in the morning, afternoon, and at
Sponsors
Boushehr University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Female and Male with the age between 18 to 55 years Long involvement approved by city scan Admitted to the hospital with Fever( = 38 C°) The breath rate = 24/min, or coughing ( before the 8th day of the disease ) Infection with covid 19, approved by PCR
Exclusion criteria
Exclusion criteria: Pregnant women Patients with kidney Disease, Patients with hypercalcemia and hypercalciuria Patients with any type of allergic diseases Having any kind of disease by which the patients can't have a proper participation Inability to behave properly( having Mental problem Auto immune diseases ( having MS, Lupus ...) Kidney Failure, Hepatitis B and C Patients with acute covid 19 symptoms
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary involvement. Timepoint: The time of measurement will be after interventions for a period of 10 days, for all the participants in both groups. Method of measurement: Results of CT scan (chest radiography). | — |
Secondary
| Measure | Time frame |
|---|---|
| CBC Test. Timepoint: The time of measurement will be after interventions for a period of 10 days, for all the participants in both groups. Method of measurement: By blood Auto-analyzer.;Erythrocyte sedimentation rate (ESR). Timepoint: The time of measurement will be after interventions for a period of 10 days, for all the participants in both groups. Method of measurement: By ESR Reader.;CRP. Timepoint: The time of measurement will be after interventions for a period of 10 days, for all the participants in both groups. Method of measurement: By biochemistry auto analyzer- spectrophotometer.;Interleukin-1. Timepoint: The time of measurement will be after interventions for a period of 10 days, for all the participants in both groups. Method of measurement: By ELISA.;Interleukin-6. Timepoint: The time of measurement will be after interventions for a period of 10 days, for all the participants in both groups. Method of measurement: By ELISA.;TNFa. Timepoint: The time of measurement will be after interventions for a period of 10 days, for all the participants in both groups. Method of measurement: By ELISA.;Alanine amino transferase. Timepoint: The time of measurement will be after interventions for a period of 10 days, for all the participants in both groups. Method of measurement: By biochemistry auto analyzer- spectrophotometer.;Aspartate Aminotransferase (AST). Timepoint: The time of measurement will be after interventions for a period of 10 days, for all the participants in both groups. Method of measurement: By biochemistry auto analyzer- spectrophotometer.;Alkaline Phosphatase (ALP). Timepoint: The time of measurement will be after interventions for a period of 10 days, for all the participants in both groups. Method of measurement: By biochemistry auto analyzer- spectrophotometer.;FBS. Timepoint: The time of measurement will be after interventions for a period of 10 days, for all the participants in both groups. Method of measurement: By biochemistry auto | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Movahed
Boushehr University of Medical Sciences
Outcome results
None listed